menu
    • menu
    [{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CD 70 CAR NK Cells","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CD 70 CAR NK Cells","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NKX019","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NKX019","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Nkarta Therapeutics \/ Adage Capital Partners LP","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Adage Capital Partners LP"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"NKX019","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nkarta Therapeutics

    Menu

    Nkarta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX019,Cyclophosphamide

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nkarta Announces Investigator-Sponsored Trial of NKX019 for Lupus Erythematosus

                            Details : NKX019 is an allogeneic CD19 directed, off-the-shelf immunotherapy candidate, which is being evaluated for the treatment of systemic lupus erythematosus.

                            Brand Name : NKX019

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 24, 2024

                            Lead Product(s) : NKX019,Cyclophosphamide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX019

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nkarta Initiates NKX019 Trial in Lupus Nephritis, Expands Pipeline to Autoimmune Diseases

                            Details : NKX019 is a cryopreserved, allogeneic CD19-targeting CAR NK-cell therapy, which is being developed for the treatment of patients with lupus nephritis.

                            Brand Name : NKX019

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : NKX019

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX019

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Adage Capital Partners LP

                            Deal Size : $240.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nkarta Announces Pricing of $240 Million Underwritten Offering

                            Details : Nkarta will use proceeds to support the clinical development of NKX019, a cryopreserved CAR NK-cell therapy targeting CD19 for relapsed/refractory non-Hodgkin lymphoma.

                            Brand Name : NKX019

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : NKX019

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Adage Capital Partners LP

                            Deal Size : $240.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX019

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

                            Details : NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors, which is investigated for the treatment of Lupus Nephritis.

                            Brand Name : NKX019

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 17, 2023

                            Lead Product(s) : NKX019

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute ...

                            Details : NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells and is being investigated for Relapsed or Refractory Acute Myeloid Leukemia.

                            Brand Name : NKX101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 27, 2023

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX019,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Re...

                            Details : NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses NK cells engineered to target the B-cell antigen CD19, a clinically validated target for B-cell cancer therapies.

                            Brand Name : NKX019

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 05, 2022

                            Lead Product(s) : NKX019,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

                            Details : NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors.

                            Brand Name : NKX101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 16, 2022

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cowen

                            Deal Size : $230.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters Full Exercise of Option t...

                            Details : Nkarta intends to use the net proceeds from the offering to fund the continued clinical development of NKX101 and NKX019, preclinical studies for research stage programs.

                            Brand Name : NKX101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 28, 2022

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cowen

                            Deal Size : $230.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cowen

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nkarta Announces Pricing of Upsized Public Offering of Common Stock

                            Details : Nkarta intends to use the net proceeds to fund the continued clinical development of NKX101 and NKX019, preclinical studies for research stage programs and the continued buildout of internal manufacturing capabilities, and for working capital and general...

                            Brand Name : NKX101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cowen

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cowen

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nkarta Announces Proposed Public Offering of Common Stock

                            Details : Nkarta intends to use the net proceeds from the offering to fund the continued clinical development of NKX101 and NKX019, preclinical studies for research stage programs and the continued buildout of internal manufacturing capabilities.

                            Brand Name : NKX101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 25, 2022

                            Lead Product(s) : NKX101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cowen

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth